Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-6184 in MDS and Symptomatic Anemia
NCT07052006Phase 2Active, not recruiting
- Sponsor
- Halia Therapeutics
- Start
- Dec 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ofirnoflast in myelodysplastic syndrome (MDS), anemia, sponsored by Halia Therapeutics. Started Dec 2023; status: active, not recruiting.
02
Drugs
ofirnoflast
03
Conditions
myelodysplastic syndrome (MDS)anemia
Beyond the preview
Go deeper on NCT07052006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052006.